Zacks Analyst Blog Highlights: Citi Trends, Alnylam Pharmaceuticals, Merck & Co., SINA Corp. and China Mobile.CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day, the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Citi Trends (Nasdaq:CTRN CTRN Colorado Technical Recruiters Network CTRN Can't Talk Right Now CTRN Certified Transport Registered Nurse CTRN Change That's Right Now, Inc (New York, NY phobia clinic) ), Alnylam Pharmaceuticals Alnylam Pharmaceuticals Inc. (NYSE: ALNY), a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on RNA interference (RNAi) in the United States. (Nasdaq:ALNY), Merck & Co. (NYSE NYSE See: New York Stock Exchange :MRK MRK Merck & Company (stock symbol) MRK Mayer-Rokitansky-Kuster (anomaly) MRK Manual Remote Keying ), SINA Corp. (Nasdaq:SINA) and China Mobile (NYSE:CHL CHL crown-heel length. ). See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673 Here are highlights from Monday's Analyst Blog: $50 Target on Citi Trends Citi Trends (Nasdaq:CTRN) reported solid third-quarter comp-store sales of -4% versus last year's 37% gain. Its total sales were about $2 million ahead of our forecast. We are increasing our 2006 and 2007 EPS (Encapsulated PostScript) A PostScript file format used to transfer a graphic image between applications and platforms. EPS files contain PostScript code as well as an optional preview image in TIFF, WMF, PICT or EPSI, the latter being an ASCII-only format. estimates by $0.03 each. We are also increasing our target price from $41 to $50, which represents a P/E-to-growth ratio of 1.2x. In our view, the stock can support a higher P/E P/E See: Price/earnings ratio multiple thanks to the company still being in the early stages of its growth cycle. The company's strong merchandising efforts, aggressive growth strategy and profitable store model bode well for its long-term growth. We reiterate our Buy rating on CTRN shares. Rec for ALNY Bumped Up Alnylam Pharmaceuticals (Nasdaq:ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference RNA interference n. A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes. , or RNAi technology. The company possesses a deep, but very early-stage therapeutic pipeline. Therapeutic candidates developed using RNAi may offer some advantages over more traditional small molecule or protein-based drugs, but it's too early to judge the value of this technology. Clinical stage work is necessary to validate the company's technology. We upgrade Alnylam shares from Sell to Hold based on the recent Nobel prize Nobel Prize, award given for outstanding achievement in physics, chemistry, physiology or medicine, peace, or literature. The awards were established by the will of Alfred Nobel, who left a fund to provide annual prizes in the five areas listed above. award to RNAi technology and the acquisition of Sirna by Merck (NYSE:MRK). Our target price is $20.00. Margins Decreasing at SINA SINA Corp. (Nasdaq:SINA) announced blockbuster financial results for the second quarter of 2006, which exceeded market census and company guidance. Its advertising revenue was mainly driven by new customers and higher spending per customer. Its advertising revenue should grow strongly in the next three years. However, its profit margins were lower than the previous year because of decreasing profit margins in its mobile value-added services. Policy changes from China Mobile (NYSE:CHL) didn't have a negative effect on its wireless business as expected. Therefore, we maintain our Hold rating on SINA shares. See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645 About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis Qualitative Analysis Securities analysis that uses subjective judgment based on nonquantifiable information, such as management expertise, industry cycles, strength of research and development, and labor relations. to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2674. About Zacks Zacks.com is a property of Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. , Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion